StockNews.com Upgrades Phibro Animal Health (NASDAQ:PAHC) to “Strong-Buy”

Phibro Animal Health (NASDAQ:PAHC) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a research note on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price objective on the stock. Barclays boosted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Finally, Bank of America raised their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $16.50.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $23.37 on Thursday. The company has a market cap of $946.49 million, a P/E ratio of 54.35, a P/E/G ratio of 0.61 and a beta of 0.51. Phibro Animal Health has a twelve month low of $9.49 and a twelve month high of $25.98. The company’s 50-day moving average price is $23.32 and its 200-day moving average price is $20.20. The company has a current ratio of 3.23, a quick ratio of 1.69 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The business had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. On average, sell-side analysts forecast that Phibro Animal Health will post 1.61 earnings per share for the current fiscal year.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran purchased 5,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were bought at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. This trade represents a 25.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 50.07% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC lifted its holdings in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Phibro Animal Health during the third quarter worth $70,000. Quantbot Technologies LP acquired a new stake in shares of Phibro Animal Health in the third quarter valued at $70,000. Summit Securities Group LLC purchased a new stake in Phibro Animal Health during the 2nd quarter worth about $83,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Phibro Animal Health by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after purchasing an additional 1,522 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.